Jean-Pierre Lindenmayer, M.D.
Dr. Jean-Pierre Lindenmayer is Clinical Professor in the Department of Psychiatry at New York University School of Medicine, and Director of the Manhattan Schizophrenia Research Program at Manhattan Psychiatric Center – Nathan Kline Institute for Psychiatric Research since 1994. Previously, he was Clinical Director at Manhattan Psychiatric Center.
Dr. Lindenmayer has conducted extensive clinical research, first as Director of the Schizophrenia Research Program at the Bronx Psychiatric Center, Albert Einstein College of Medicine, before joining the Manhattan Psychiatric Center and the Nathan Kline Institute for Psychiatric Research.
Dr. Lindenmayer’s particular interest in research has included the development of new pharmacological and neurocognitive treatments for schizophrenia patients. He has conducted a wide range of NIMH funded studies in suboptimal treatment response in schizophrenia; studies of early Phase II proof-of-concept trials of new antipsychotics; studies of metabolic side effects of atypical antipsychotics; and novel non-pharmacological neurocognitive interventions for cognitive deficits in schizophrenia. In collaboration with other Principal Investigators, he has been involved in using a broad range of investigative tools, including psychopathological and cognitive assessments, functional imaging, and genotyping. He has significantly contributed to the development of the Positive and Negative Syndrome Scale (PANSS and SCI-PANSS), which has become an internationally accepted instrument for the assessment of schizophrenia symptoms. He has developed the InterSept Scale for Suicidal Ideation (ISST), an instrument to measure suicidal thinking in patients with schizophrenia, and the PANSS Excitement Scale. He was one of the first to introduce the syndromal approach and measurement of schizophrenia psychopathology using the five PANSS-derived Factor subscales. On the neurocognitive side, Dr. Lindenmayer has championed the introduction of a systematic program of computer based neurocognitive remediation for patients with chronic schizophrenia in the public psychiatric sector.
Dr. Lindenmayer’s work has led to numerous publications and articles in leading scientific journals, and several books as well as book chapters and presentations at national and international meetings. He has received the Dr. Lewis Opler Memorial Award from NAMI-NYS. This award recognizes the impact Dr. Lindenmayer has made with his decades of work in research and support for those affected by mental health conditions.